Probiotics are bacterial preparations that alter the bacterial flora in the bowel to cause a beneficial effect. Animal research has demonstrated that probiotics have barrier enhancing, antibacterial, immune modulating and anti-inflammatory effects which may have a positive effect in the management of SIBO in humans. Lactobacillus casei has been found to be effective in improving breath hydrogen scores after 6 weeks of treatment presumably by suppressing levels of a small intestinal bacterial overgrowth of fermenting bacteria. The multi-strain preparation VSL#3 was found to be effective in suppressing SIBO. Lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei have all demonstrated effectiveness in the treatment and management of SIBO. Conversely lactobacillus fermentum and saccharomyces boulardii have been found to be ineffective. A combination of lactobacillus plantarum and lactobacillus rhamnosus has been found to be effective in suppressing bacterial overgrowth of abnormal gas producing organisms in the small intestine.
saccharomyces boulardii has been clinically shown to reverse gastroparesis after cancer treatment
Probiotics are superior to antibiotics in the treatment of SIBO. A combination of probiotic strains has been found to produce better results than therapy with the antibiotic drug metronidazole and probiotics have been found to be effective in treating and preventing secondary lactase deficiency and small intestinal bacteria overgrowth in individuals suffering from post-infectious irritable bowel syndrome. Probiotics taken in uncomplicated cases of SIBO can usually result in the individual becoming symptom free. Probiotic therapy may need to be taken continuously to prevent the return of overgrowth of gas producing bacteria. A study by the probiotic yogurt producer Nestlé found that probiotic yogurt may also be effective in treating SIBO with evidence of reduced inflammation after 4 weeks of treatment. (Wiki)
New evidence suggests that fibre reduces diarrhoea associated with enteral tube feeding. Furthermore, a new probiotic mixture (VSL-3, viable lyophilized bacteria of 4 strains of Lactobacillus, 3 strains of Bifidobacterium and 1 strain of Streptococcus thermophilus (VSL Pharmaceuticals, Inc,. Ft. Lauderdale, FL. USA)) was of benefit in the treatment of bacterial overgrowth and in the prevention of diarrhoea after pelvic radiation treatment.
A molecular basis for biﬁdobacterial enrichment in the infant gastrointestinal tract…..Expression studies indicate that many of these key functions are only induced during growth on milk oligosaccharides and not expressed during growth on other prebiotics. (Garrido D., 2012)
Immune Health News